X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs DISHMAN PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS DISHMAN PHARMA NOVARTIS/
DISHMAN PHARMA
 
P/E (TTM) x 347.8 25.1 1,386.2% View Chart
P/BV x 17.1 3.3 511.6% View Chart
Dividend Yield % 1.7 0.7 253.7%  

Financials

 NOVARTIS   DISHMAN PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-16
DISHMAN PHARMA
Mar-16
NOVARTIS/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs982374 262.3%   
Low Rs556129 431.5%   
Sales per share (Unadj.) Rs252.9197.8 127.9%  
Earnings per share (Unadj.) Rs62.121.2 293.0%  
Cash flow per share (Unadj.) Rs63.334.7 182.3%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.30.8 163.6%  
Book value per share (Unadj.) Rs363.6179.9 202.1%  
Shares outstanding (eoy) m31.9680.69 39.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.01.3 239.0%   
Avg P/E ratio x12.411.9 104.3%  
P/CF ratio (eoy) x12.27.2 167.7%  
Price / Book Value ratio x2.11.4 151.2%  
Dividend payout %16.19.4 170.6%   
Avg Mkt Cap Rs m24,58020,306 121.1%   
No. of employees `0000.80.8 90.7%   
Total wages/salary Rs m1,8015,355 33.6%   
Avg. sales/employee Rs Th10,748.919,252.7 55.8%   
Avg. wages/employee Rs Th2,395.26,459.5 37.1%   
Avg. net profit/employee Rs Th2,641.12,064.1 128.0%   
INCOME DATA
Net Sales Rs m8,08315,961 50.6%  
Other income Rs m829265 312.5%   
Total revenues Rs m8,91316,226 54.9%   
Gross profit Rs m2344,103 5.7%  
Depreciation Rs m371,091 3.4%   
Interest Rs m2944 0.2%   
Profit before tax Rs m1,0252,334 43.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m171 1,518.2%   
Extraordinary Inc (Exp) Rs m1,6960-   
Tax Rs m752624 120.6%   
Profit after tax Rs m1,9861,711 116.1%  
Gross profit margin %2.925.7 11.3%  
Effective tax rate %73.426.7 274.5%   
Net profit margin %24.610.7 229.2%  
BALANCE SHEET DATA
Current assets Rs m12,67811,018 115.1%   
Current liabilities Rs m2,4339,517 25.6%   
Net working cap to sales %126.79.4 1,347.8%  
Current ratio x5.21.2 450.1%  
Inventory Days Days33110 29.6%  
Debtors Days Days2235 64.6%  
Net fixed assets Rs m6916,304 0.4%   
Share capital Rs m160161 99.0%   
"Free" reserves Rs m11,46012,907 88.8%   
Net worth Rs m11,62114,516 80.1%   
Long term debt Rs m04,189 0.0%   
Total assets Rs m14,40029,805 48.3%  
Interest coverage x570.53.5 16,436.2%   
Debt to equity ratio x00.3 0.0%  
Sales to assets ratio x0.60.5 104.8%   
Return on assets %13.88.9 154.9%  
Return on equity %17.111.8 145.0%  
Return on capital %23.617.5 134.5%  
Exports to sales %0.724.8 3.0%   
Imports to sales %18.63.7 497.6%   
Exports (fob) Rs m603,956 1.5%   
Imports (cif) Rs m1,503596 252.0%   
Fx inflow Rs m1864,952 3.8%   
Fx outflow Rs m1,821697 261.3%   
Net fx Rs m-1,6354,255 -38.4%   
CASH FLOW
From Operations Rs m2,5312,786 90.8%  
From Investments Rs m-8,270-1,529 540.9%  
From Financial Activity Rs m-386-941 41.0%  
Net Cashflow Rs m-6,125316 -1,935.7%  

Share Holding

Indian Promoters % 0.0 61.4 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 3.7 54.1%  
FIIs % 1.6 12.7 12.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 22.1 97.3%  
Shareholders   41,647 46,261 90.0%  
Pledged promoter(s) holding % 0.0 35.8 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   NATCO PHARMA  PANACEA BIOTECH  WOCKHARDT LTD.  ABBOTT INDIA  PLETHICO PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Vishal Sikka's Infosys Exit, White House Shake up & Cues to Watch Out Today(Pre-Open)

Indian share markets ended lower on Friday but gained during the overall week. At the closing bell on Friday, BSE Sensex closed lower by 271 points and the NSE Nifty finished down 67 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Profitable Investment in the History of the World(Vivek Kaul's Diary)

Aug 8, 2017

'Yes, it looks like a bubble. And, yes, it's like buying a lottery ticket. But there's something happening that has never happened before. It's an evolutionary leap in money itself.'

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Aug 18, 2017 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE NOVARTIS WITH

MARKET STATS